CLINICAL TRIALS PROFILE FOR TACRINE HYDROCHLORIDE

All Clinical Trials for TACRINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00006187 ↗	The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease	Terminated	Merck Sharp & Dohme Corp.	Phase 3	1969-12-31	This is a 15-month study with two phases. During the first 12-month phase of this study, patients will be randomly assigned to receive either active study drug or placebo (approximately half of all patients will be on active study drug, the other half on placebo). The second phase is a 3-month randomized withdrawal period. For this phase approximately 10% of the patients will remain on the active drug.
NCT00190021 ↗	Donepezil Treatment of Psychotic Symptoms in Dementia Patients	Unknown status	Beersheva Mental Health Center	Phase 3	1969-12-31	Conventional psychotropic medications may be used to treat behavioral disturbances and psychotic symptoms in patients with dementia and they are the drugs of choice for treating delusions and hallucinations. However the sensitivity to side effects in these patients often restricts the use of these agents (2, 3). Although, atypical antipsychotics have some advantages compared with conventional neuroleptics, they also are associated with side effects (5, 6). Cholinesterase inhibitors (ChEIs) enhance neuronal transmission by increasing the availability of acetylcholine in muscarinic and nicotinic receptors. According to findings of some researchers ChEIs have psychotropic effects and may play an important role in controlling neuropsychiatric and behavioral disturbances in patients with Alzheimer's disease (7-10). These agents may also contribute to the management of other disorders with cholinergic system abnormalities and neuropsychiatric symptoms such as visual hallucinations (11). Donepezil is a piperidine-based reversible, noncompetitive ChEI, which is indicated in the management of patients with Alzheimer's disease of mild to moderate severity (12-14). Preliminary observations suggest the possible value of ChEIs in the amelioration of psychotic symptoms in patients with dementia of the Alzheimer's type (DAT), dementia with Lewy bodies and patients suffering from Parkinson's disease (11-18). The results of our study (18) indicate that the addition of donepezil to perphenazine resulted in qualitatively superior clinical gains compared to higher doses of neuroleptic therapy without donepezil. The finding of the pilot study although impressive, stem from data regarding a rather small sample. The present (second) phase of the study will include a larger sample of patients. We now intend to examine 80 inpatients, aged 65-90 years old, suffering from DAT.
NCT00551161 ↗	Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease	Completed	Forest Laboratories	Phase 4	2007-08-01	We are studying subjects with mild to moderate Alzheimer's disease who have been on a stable dose of any cholinesterase inhibitor [donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne)] for at least 3 months, and have not previously taken memantine (Namenda). This is an open-label study, with magnetic resonance spectroscopy (MRS) as the primary outcome measure, along with neuropsychological testing, and optional lumbar puncture, evaluating patients on their stable dose of a cholinesterase inhibitor over 24 weeks, followed by another 24 weeks on memantine in combination with stable dose of cholinesterase inhibitor. The purpose of this study is to characterize the progression of disease using MRS, cerebrospinal fluid (CSF) biomarkers, and cognitive outcome measures, and to determine whether changes in cognitive function on neuropsychological testing are correlated to changes in MR spectroscopic and/or CSF biomarkers.
NCT00551161 ↗	Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease	Completed	Northwell Health	Phase 4	2007-08-01	We are studying subjects with mild to moderate Alzheimer's disease who have been on a stable dose of any cholinesterase inhibitor [donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne)] for at least 3 months, and have not previously taken memantine (Namenda). This is an open-label study, with magnetic resonance spectroscopy (MRS) as the primary outcome measure, along with neuropsychological testing, and optional lumbar puncture, evaluating patients on their stable dose of a cholinesterase inhibitor over 24 weeks, followed by another 24 weeks on memantine in combination with stable dose of cholinesterase inhibitor. The purpose of this study is to characterize the progression of disease using MRS, cerebrospinal fluid (CSF) biomarkers, and cognitive outcome measures, and to determine whether changes in cognitive function on neuropsychological testing are correlated to changes in MR spectroscopic and/or CSF biomarkers.
NCT01406522 ↗	Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics	Withdrawn	Midwest Biomedical Research Foundation	Phase 2	2012-10-01	No medications are currently available for treatment of psychostimulant addiction, a compulsive preoccupation with use of cocaine and related compounds. Tacrine, a medication that is currently prescribed for Alzheimer's disease, can decrease the amount of cocaine injections that laboratory animals choose to inject by vein. This project will determine if tacrine can also decrease cocaine-motivated behavior for human subjects in a laboratory setting.
NCT01495195 ↗	Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	2012-02-01	No medications are currently available for treatment of psychostimulant addiction, a compulsive preoccupation with use of cocaine and related compounds. Donepezil is a medication that is currently prescribed for Alzheimer's disease, and selegiline is a medication used for treatment of Parkinson's Disease. Both of these medications can decrease the amount of cocaine injections that laboratory animals choose to inject by vein. This project will determine if combined treatment with donepezil and selegiline can also decrease cocaine-motivated behavior for human subjects in a laboratory setting.
NCT01495195 ↗	Combined Donepezil and Selegiline Effects on Cocaine-Reinforced Behavior	Completed	Midwest Biomedical Research Foundation	Phase 2	2012-02-01	No medications are currently available for treatment of psychostimulant addiction, a compulsive preoccupation with use of cocaine and related compounds. Donepezil is a medication that is currently prescribed for Alzheimer's disease, and selegiline is a medication used for treatment of Parkinson's Disease. Both of these medications can decrease the amount of cocaine injections that laboratory animals choose to inject by vein. This project will determine if combined treatment with donepezil and selegiline can also decrease cocaine-motivated behavior for human subjects in a laboratory setting.

Clinical Trial Conditions for TACRINE HYDROCHLORIDE

Condition Name

Condition Name for TACRINE HYDROCHLORIDE
Intervention	Trials
Alzheimer Disease	2
Cocaine Dependence	1
Cocaine Use Disorders	1
Dementia of Alzheimer Type	1

Condition MeSH

Condition MeSH for TACRINE HYDROCHLORIDE
Intervention	Trials
Alzheimer Disease	3
Dementia	1
Cocaine-Related Disorders	1

Clinical Trial Locations for TACRINE HYDROCHLORIDE

Trials by Country

Trials by Country for TACRINE HYDROCHLORIDE
Location	Trials
United States	19
Israel	1

Trials by US State

Trials by US State for TACRINE HYDROCHLORIDE
Location	Trials
Missouri	2
New York	2
Massachusetts	1
Illinois	1
Florida	1

Clinical Trial Progress for TACRINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for TACRINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
Phase 2	2

Clinical Trial Status

Clinical Trial Status for TACRINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	2
Terminated	1
Unknown status	1

Clinical Trial Sponsors for TACRINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for TACRINE HYDROCHLORIDE
Sponsor	Trials
Midwest Biomedical Research Foundation	2
Merck Sharp & Dohme Corp.	1
Beersheva Mental Health Center	1

Sponsor Type

Sponsor Type for TACRINE HYDROCHLORIDE
Sponsor	Trials
Other	4
Industry	2
NIH	1

TACRINE HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: April 23, 2026

Tacrine Hydrochloride: Clinical Trial Update, Market Analysis, and Projection

What is tacrine hydrochloride’s clinical status today?

Tacrine hydrochloride is the first-in-class acetylcholinesterase inhibitor historically used for Alzheimer’s disease, approved in the US in the early 1990s. Clinically, the drug’s utility has been constrained by safety and monitoring requirements, most notably hepatotoxicity.

Key clinical and regulatory anchors

• US approval (Alzheimer’s disease): tacrine was approved in 1993 (brand: Cognex).
• Reason for loss of mainstream use: hepatotoxicity requiring frequent liver function monitoring; narrow benefit-risk in routine care versus better-tolerated next-generation agents (e.g., donepezil, rivastigmine, galantamine).
• Current market reality: tacrine is now a niche historical product. Real-world prescribing is limited and driven more by availability and specific patient circumstances than by guideline-preferred use.

Clinical trials: activity level Publicly available clinical-trial ecosystems (e.g., ClinicalTrials.gov) show that ongoing interventional studies for tacrine are scarce versus comparator cholinesterase inhibitors. The practical read-through for businesses is that tacrine is not positioned as a major modern clinical development platform; investment focus typically shifts to newer agents, reformulations, and combination strategies rather than re-litigating tacrine’s core safety profile.

Commercial implication for R&D

• If the objective is new clinical efficacy evidence, tacrine faces headwinds: hepatotoxicity mitigation, monitoring burden, and competition from established cholinesterase inhibitors and later-stage disease-modifying approaches.
• If the objective is product lifecycle or off-label access, the “clinical update” is more about supply continuity, label constraints, and pharmacovigilance than about new pivotal trials.

Where does tacrine sit in the market today?

Tacrine hydrochloride’s market is best characterized as legacy and low-growth, not as a growth franchise. Its adoption path peaked in the early adoption wave after approval and then contracted sharply as safer agents gained market share.

Market structure

• Cholinesterase inhibitor class: historically competitive in symptomatic Alzheimer’s management, but tacrine is not a first-line choice in current practice patterns.
• Therapy drivers: reimbursement behavior, formulary placement, and monitoring logistics heavily influence utilization. Tacrine’s liver monitoring requirements reduce formulary attractiveness even when pharmacodynamics match class expectations.
• Competitive set: donepezil, rivastigmine, and galantamine dominate standard symptomatic treatment use in most markets.

Supply and access

Tacrine availability is typically limited relative to dominant cholinesterase inhibitors. This matters for projection: if tacrine supply is constrained or discontinued in specific regions, effective demand can remain latent and re-emerge only when supply returns.

Business reality

• Demand is more sensitive to product availability and pricing than to new prescriber enthusiasm.
• Volume is likely driven by historical prescriber familiarity, specific patient tolerability profiles, and local procurement patterns rather than broad switching.

What do historical utilization patterns imply for projection?

Because tacrine is not a modern clinical development priority, projections depend primarily on: 1) continued availability (supply chain and regulatory status in key geographies), 2) substitution pressure from better-tolerated cholinesterase inhibitors, 3) budget and monitoring burden that affects payer and provider behavior.

Projection framework

A workable projection model for tacrine is to treat it as a maintenance product rather than a growth product:

• Base demand: legacy demand plateau near the floor of available supply.
• Downward drift: driven by competitive substitution and prescriber migration over time.
• Scenario volatility: depends on whether tacrine products are discontinued in jurisdictions or remain consistently stocked.

3-scenario market projection (directional, use-case driven)

The table below expresses projection as indexed trend rather than absolute revenue, because tacrine’s market footprint is small and varies substantially by country and formulation availability.

Time horizon	Base scenario (indexed demand)	Downside scenario (indexed demand)	Upside scenario (indexed demand)
Next 12 months	100 (flat-to-slight decline)	95	105 (if supply improves)
2-3 years	90-92	80-85	95-98
4-5 years	80-85	65-75	90-93

Interpretation for decision-makers

• Base case: low single-digit annual erosion as standard prescribing continues to shift to dominant agents.
• Downside case: sharper decline if supply is reduced, monitoring capacity becomes more restrictive, or product exits formularies.
• Upside case: modest stabilization if tacrine is maintained with reliable supply and if niche demand persists.

How does safety profile affect market forecast and clinical planning?

Tacrine’s hepatotoxicity is central to both clinical and commercial outcomes. Any attempt to re-expand tacrine use must address:

• treatment initiation requirements,
• liver function monitoring schedule,
• patient eligibility boundaries,
• risk management consistency across health systems.

Practical constraints

• Monitoring burden favors agents with simpler safety management.
• Clinician adherence to monitoring protocols can vary across settings, lowering the effective addressable market even when pharmacology is unchanged.

Impact on clinical trial design (if new trials exist)

Trials require tighter safety monitoring and governance, increasing cost per patient and extending timelines. That raises the threshold for commercial viability.

What is the competitive landscape for tacrine in Alzheimer’s symptomatic therapy?

Tacrine operates in a crowded market where current standard symptomatic care is led by:

• Donepezil (once-daily, generally better tolerability and monitoring simplicity)
• Rivastigmine (oral and transdermal options)
• Galantamine (structured dosing and established use)

In competitive terms:

• tacrine faces a “switching tax” for prescribers and payers because it requires more operational effort (monitoring).
• even where efficacy in symptom control is comparable, ease-of-use often drives formulary and prescribing outcomes.

What’s the investment and R&D signal from the tacrine development ecosystem?

From a drug-patent and R&D lens, tacrine is best treated as a low-propensity re-development candidate unless a specific reformulation, delivery change, or risk-mitigation program is planned. In practice:

• New clinical efficacy trials are unlikely to be commercially justified in a market dominated by better-tolerated cholinesterase inhibitors.
• Replacement therapies and later-line disease frameworks reduce the upside of re-litigating symptomatic monotherapy.

Patent and exclusivity angle (what it means for market projections)

Tacrine has a long market history. The practical outcome is that commercial opportunities now are driven by:

• generic entry and competitive pricing,
• manufacturing capacity and product availability,
• regulatory status in specific countries.

For projections, this translates into:

• price erosion typical of off-patent, legacy molecules,
• demand stabilization only when supply remains reliable and monitoring workflows are manageable.

Clinical trial update: where tacrine’s evidence base is strongest

Tacrine’s strongest evidence base is historical symptomatic efficacy in Alzheimer’s disease. The modern clinical environment values:

• tolerability and monitoring,
• adherence to pragmatic treatment settings,
• comparative use patterns versus standard-of-care.

This shifts the “center of gravity” away from tacrine’s historical trials toward real-world tolerability and operational feasibility.

Key takeaways

• Tacrine hydrochloride is a legacy acetylcholinesterase inhibitor with limited contemporary clinical momentum due to hepatotoxicity risk and associated monitoring burden.
• The market is niche and low-growth, with demand mainly sustained by availability, formulary residue, and specific patient/provider circumstances rather than broad adoption.
• Projections are best modeled as a maintenance franchise: expect continued slow erosion in most scenarios, with modest stabilization only if supply and access remain consistent.
• Any expansion thesis requires more than efficacy: it must solve for risk management and monitoring practicality relative to dominant cholinesterase inhibitors.

---

FAQs

1) Is tacrine hydrochloride used as first-line therapy for Alzheimer’s disease now?

No. Standard practice favors better-tolerated cholinesterase inhibitors with simpler monitoring requirements.

2) Why did tacrine lose market share historically?

Hepatotoxicity drove frequent liver function monitoring and reduced its practicality versus competing agents.

3) Are there many active clinical trials for tacrine today?

Clinical-trial activity for tacrine is limited compared with modern Alzheimer’s programs, reflecting low commercial development momentum.

4) What drives tacrine demand most in the current market?

Supply availability, local formulary access, and operational capacity for liver monitoring drive utilization more than new evidence.

5) What is the most likely market trajectory over the next 5 years?

Slow decline in most scenarios, with modest stabilization possible if supply and access remain consistent.

---

References

[1] FDA. (1993). Cognex (tacrine hydrochloride) approval letter / regulatory action (historical approval record). U.S. Food and Drug Administration. https://www.fda.gov/
[2] ClinicalTrials.gov. Tacrine hydrochloride clinical trials search results. U.S. National Library of Medicine. https://clinicaltrials.gov/
[3] Lexicomp / Drug Monographs. Tacrine hydrochloride safety and monitoring information (hepatotoxicity and liver function monitoring). Wolters Kluwer. https://www.wolterskluwer.com/
[4] PubMed. Tacrine and acetylcholinesterase inhibitor evidence in Alzheimer’s disease (historical efficacy and safety literature). National Center for Biotechnology Information. https://pubmed.ncbi.nlm.nih.gov/